Fluorescence cystoscopy at bladder cancer: Present trials;Die fluoreszenzzystoskopie beim harnblasenkarzinom: Aktueller stellenwert

Urologe - Ausgabe A

Volumn 46, Issue 11, 2007, Pages 1519-1527

  Zaak, D ^a,b,e   Karl, A ^a   Stepp, H ^a   Tritschler, S ^a   Tilki, D ^a   Burger, M ^c   Wieland, W F ^c   Knuechel, R ^d   Stief, C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Praxis und Belegabteilung für Urologie und Kinderurologie   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e NONE   (Germany)

Author keywords

Bladder cancer; Fluorescence cystoscopy; Hexyl ALA ester; Photodynamic diagnosis

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; DIAGNOSTIC AGENT; PHOTOSENSITIZING AGENT;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER SURGERY; CYSTOSCOPY; EARLY DIAGNOSIS; FLUORESCENCE ANALYSIS; HUMAN; PHOTODYNAMICS; RECURRENT CANCER; REVIEW; TRANSURETHRAL RESECTION;

AMINOLEVULINIC ACID; BIOPSY; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; FLUORESCENCE; HUMANS; PHOTOSENSITIZING AGENTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 36249026466     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-007-1563-7     Document Type: Review

References (43)

1. Alken P, Siegsmund M, Gromoll-Bergmann K et al. (2007) A randomized controlled multicentre trial to compare the effects of transurethral resection of bladder carcinomas under 5-ALA induced fluorescence light to conventional white light. Poster presented at Annual EAU congress, March 21-24, 2007, Berlin, Germany
2. Avritscher EB, Cooksley CD, Grossman HB et al. (2006) Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68: 549-553
3. Babjuk M, Soukup V, Petrik R et al. (2005) 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 96: 798-802
4. Burger M, Zaak D, Stief CG et al. (2007) Photodynamic diagnostics and noninvasive bladder cancer: Is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 52: 142-147
5. D'Hallewin MA, Kamuhabwa A, Roskams T et al. (2002) Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int 89: 760-763
6. Daniltchenko DI, Riedl CR, Sachs MD et al. (2005) Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174: 2129-2133
7. Denzinger S, Burger M, Walter B et al. (2007) Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acidinduced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69: 675-679
8. Filbeck T, Pichlmeier U, Knuechel R et al. (2002) Do patients profit from 5-aminolevulinic acid-induced fluorescence diagnosis in transurethral resection of bladder carcinoma? Urology 60: 1025-1028
9. Filbeck T, Roessler W, Knüchel R et al. (1999) 5-aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors. Urology 53: 77-81
10. Fradet Y, Grossman HB, Gomella L et al. PC B302/01 Study Group (2007) A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 178: 68-73
11. Grimbergen MCM, Van Swol CFP, Jonges TGN et al. (2003) Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 44: 51-56
12. Grossman HB, Gomella L, Fradet Y et al. PC B302/01 Study Group (2007) A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 178: 62-67
13. Hungerhaber E, Stepp H, Kriegmair M et al. (2007) Seven years expexience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69(2): 260-264
14. Jakse G, Algaba F, Malmstrom PU, Oosterlinck W (2004) A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol 45: 539-546
15. Jichlinski P, Guillou L, Karlsen SJ et al. (2003) Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial biadcler cancer - a multicenter study. J Urol 170(1): 226-229
16. Jocham D, Baumgartner R, Fuchs N et al. (1989) Fluorescence diagnosis of porphyrin-marked urothelial tumors. Status of experimental development. Urologe A 28 59-64
17. Jocham D, Witjes F, Wagner S et al. (2005) Improved detection and treatment of bladder cancer using Hexvix imaging: a prospective phase III multi-centre study. J Urol 174: 862-866
18. Karakiewicz PI, Benayoun S, Zippe C et al. (2006) Institutional variability in the accuracy of urinary cytology for predicting recurrences of transitional cell carcinoma of the bladder. BJU Int 97: 997-1001
19. Karl A, Reich O, Tritschler S et al. (2006) Positive cytology, but negative white light endoscopy: an indication for fluorescence cystoscopy in bladder cancer? J Urol 175(Suppl 4): 288
20. Kirkali Z, Chan T, Manoharan M et al. (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66(Suppl 1): 4-34
21. König F, McGovern FJ, Larne R et al. (1999) Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced 5-aminolaevulinic acid. BJU Int 83: 129-135
22. Krieg RC, Messmann H, Rauch J et al. (2002) Metabolic characterization of tumor cellspecific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells. Photochem Photobiol 76: 518-525
23. Kriegmair M, Baumgartner R, Knüchel R et al. (1994) Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 44: 836-841
24. Kriegmair M, Baumgartner R, Knüchel R et al. (1996) Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 155: 105-110
25. Kriegmair M, Zaak D, Rothenberger KH et al. (2002) Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 168: 475-478
26. Lange N, Jichlinski P, Zellweger M et al. (1999) Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 80: 185-193
27. Marti A, Jichlinski P, Lange N et al. (2003) Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 170: 428-432
28. Obermann EC, Junker K, Stoehr R et al. (2003) Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 199: 50-57
29. Oosterlinck W, Lobel B, Jakse G et al. EAU (European Association of Urology) Working Group on Oncological Urology (2002) Guidelines on bladder cancer. Eur Urol 41: 105-112
30. Penkoff H, Steiner H, Dajc-Sommerer E et al. (2007) Transurethral detection and resection of bladder carcinomas under white or 5-ALA induced fluorescence light: Results of the First Double-Blind Placebo-Controlled Clinical Trial. Abstract 1085 presented at Annual AUA congress, May 19-24, 2007, Anaheim, CA
31. Riedl CR, Daniltchenko D, Koenig F et al. (2001) Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 165: 1121-1123
32. Robert-Koch-Institut (2006) http://www.rki.de. RKI, Berlin
33. Schmidbauer J, Witjes F, Schmeller N et al. (2004) Improved detection of urothelial carcinoma in situ with hexaminolevulinate (HAL) fluorescence cystoscopy. J Urol 171: 135-138
34. Stenzl A, Höltl L, Bartsch G (2001) Fluorescence assisted transurethral resection of bladder tumours: is it cost effective? Eur Urol 39: 31
35. Tritschler S, Scharf S, Karl A et al. (2007) Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 51: 403-407
36. Meijden P van der, Sylvester R, Oosterlinck W et al. (2005) EAU Guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 48: 363-371
37. Oers JM van, Adam C, Denzinger S et al. (2006) Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 119: 1212-1215
38. Witjes JA, Moonen PMJ, Hijden AG van der (2005) Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. Eur Urol 47: 319-322
39. Whitmore WF Jr, Bush IM (1965) Ultraviolet cystoscopy in patients with bladder cancer. Trans Am Assoc Genitourin Surg 57: 149-155
40. Zaak D, Hungerhuber E, Schneede P et al. (2002) Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 95: 1234-1238
41. Zaak D, Kriegmair M, Stepp H et al. (2001) Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid - results of 1012 fluorescence endoscopies. Urology 57: 690-694
42. Zaak D, Frimberger D, Stepp H et al. (2001) Quantification of 5-aminolevulinic acid induced fluorescence improves the specificity of bladder cancer detection. J Urol 166: 1665-1669
43. Zaak D, Karl A, Knüchel R et al. (2005) Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int 96: 217-222